Do we have the SFA algorithm figured out? Dr. @jcgeorgemd (@SCAI) reviews CTO access strategies, the FACTOR score, adjunctive tools, atherectomy, DCB/DES, and the role of imaging—plus where gaps remain in our toolbox. 🎥 Watch now on #Vumedi - https://t.co/gYI5qPZ33t #Cardiology

The new frontier in CV medicine: cardiometabolic-kidney-liver syndrome. Dr. @PamTaubMD explains why early, holistic management with GLP-1s, SGLT2is, and lifestyle is essential to prevent HF, CKD, and MASH progression. 🎥 Watch now on #Vumedi -

Thick LV walls. Low-voltage ECG. HFpEF that doesn’t respond as expected. Could it be amyloidosis? 🫀 Dr. Norman Lepor shares the key red flags and new therapies you can’t afford to miss. 🎥 Watch now on #Vumedi - https://t.co/3ijhjNzvY9 #Cardiology #HFpEF #Amyloidosis

Air pollution, noise, and temperature extremes aren’t just environmental issues—they’re potent CV risk factors. Dr. Andrew Freeman shows how these exposures drive inflammation, arrhythmias, and cardiac events, and what clinicians can do. 🎥 Watch now on #Vumedi -

Diagnosing HFpEF isn’t straightforward. Dr. Uri Elkayam reviews pitfalls of BNP, echo, and scoring systems—showing why exercise hemodynamics often reveal what resting tests miss. A must-watch for HF specialists. 🎥 Watch now on #Vumedi - https://t.co/ZFxklGru4Q #HeartFailure

From plant-based diets to the role of GLP-1s, leading experts Drs. @DrOstfeld , Belardo, Wood & @Kpakanati3 (@ASPCardio) discuss how to tailor nutrition for CV prevention & long-term success. Practical, evidence-based strategies for every patient. 🎥 Watch now on #Vumedi

From P2Y12 choice to LDL-C <55 mg/dL, complete revascularization, radial access, and cardiac rehab— @DrM_ODonoghue breaks down the top practice-changing updates in the 2025 ACC/AHA ACS Guidelines. 🎥 Watch now on #Vumedi - https://t.co/5z24I7qBtF #Cardiology #ACSGuidelines #PCI

LIMAs are the gold standard for CABG—but they’re not invincible. Dr. John Lasala shares 3 challenging cases of LIMA dissection, aneurysm, & complications post-bypass, with lessons for PCI & surgical teams. 🎥 Watch on #Vumedi https://t.co/SsBlluUnYI #VumediCardio #CABG #PCI

From @PVRI Drug Discovery & Development Symposium 2025 — Dr. @SudarRajagopal (@DukeMedSchool) discusses the power & limits of imaging in proving disease-modifying effects in PH drug trials. Watch on Vumedi: https://t.co/4OCoBicPgS #PulmonaryHypertension #PVRI #Vumedi

In >270k ASCVD patients, higher Lp(a) levels were strongly linked to recurrent CV events—across sex & race. Aggressive LDL-C lowering may help mitigate risk. Diane Macdougall & the @FamilyHeartFdn present key findings. 🎥 Watch now on #Vumedi -

Even with zero or mild coronary calcium, patients remain at risk. Dr. Kenneth Chan (@Heart_SCCT ) shows how FAI Score from CT imaging identifies coronary inflammation—predicting mortality & MACE beyond calcium scoring. 📹 Watch now on #Vumedi -

Tirzepatide cut HFpEF events by 38%. Semaglutide reduced CKD progression by 24% & MACE by 20%—even without diabetes. Dr. Kim Connelly reviews the GLP-1 era in cardiometabolic care. 🎥 Watch now on #Vumedi https://t.co/SZRD8lFlqJ #VumediCardio Credit: Collaborative CME and

At Houston Shock 2024, Dr. Joyce Wald (@PennMedicine) breaks down her first-choice drugs for managing cardiogenic shock — and why. 📺 Watch on Vumedi: https://t.co/aIejGDT1BJ #CardiogenicShock #HoustonShock #Vumedi #CriticalCare @Cardio_Vumedi

From antiplatelet choice to LDL targets, radial access, imaging, and timing of PCI—Dr. Deepak Bhatt breaks down the Top 10 ACS 2025 Guideline updates that may challenge your practice patterns. 🎥 Watch now on #Vumedi for practical, evidence-based takeaways

From Cleveland Clinic’s 2025 Pulmonary Hypertension Summit → now on #Vumedi: @SteveMathaiMD (@HopkinsMedicine) connects the dots on PH in connective tissue disease — from diagnosis to treatment advances. 📺 https://t.co/Ar2vQmjNje #PulmonaryHypertension

2024–2025 delivered game-changing PCI data. ECMO in shock, DCBs, OCT/IVUS, FFR in multivessel CAD, antiplatelet duration—Dr. Samin Sharma breaks down the Top 10 Coronary Intervention Trials that could change your practice. 🎥 Watch now on #Vumedi

Early and sustained LDL-C reduction matters. Dr. Kausik Ray, with the @nationallipid, shares why earlier therapy and long-term control are key to preventing ASCVD events—no matter the treatment choice. 📹 Watch now on #Vumedi - https://t.co/6kLZm8o3FB #Cardiology #LDL

What were 2025’s most practice-changing CV trials? From aspirin management before surgery to PFA in AFib and SGLT2 outcomes in HF, Dr. Christopher Good reviews the top 5 studies every cardiologist should know. 📹 Watch now on #Vumedi - https://t.co/ugDawjaqh7 #VumediCardio #CV

AI is reshaping heart failure care. Dr. @NirUrielMD shares how algorithms can detect cardiomyopathy on routine EKGs, predict outcomes, and even guide CRT optimization. What’s next for HF management with AI? 📹 Watch now on #Vumedi-

Women present unique challenges in CVD and arrhythmia care. Dr. Poulina Uddin (Scripps Health) explores underrecognized symptoms, hormonal impacts, microvascular disease, SCAD, and arrhythmia risk. Essential insights for every clinician. 📹 Watch now on #Vumedi -